Stockreport

Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine [TheStreet.com]

TENCENT HLDGS UNSP/ADR  (TCEHY) 
NASDAQ:AMEX Investor Relations: tencent.com/en-us/investor.html
PDF HONG KONG and HANGZHOU, China April 30, 2026 /PRNewswire/ -- Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, [Read more]